clinical

Phase I Trials

Involves a small group of healthy volunteers or patients to test for adverse effects, tolerability, and pharmacokinetic properties.

Phase II Trials

Expands to a larger group of patients to evaluate pharmacodynamic effects and identify potential therapeutic candidates.

Phase III Trials

Comprises double-blind, randomized trials involving thousands of patients to compare the new drug with existing alternatives or placebos.

Phase IV Trials

Consists of post-marketing surveillance to monitor rare or long-term adverse effects in a large patient population.

Good Clinical Practice (GCP)

Guidelines ensuring meticulous patient group selection, data collection, statistical analysis, and documentation in clinical trials.

Pharmacoeconomic Analysis

Assessment of clinical and economic benefits typically incorporated during Phase III trials.

Investigational New Drug (IND)

Status required for manufacturers to apply for before testing their drug in humans.

FDA Approval Timeline

The drug development process, including clinical trials, spans 7 to 12 years, with regulatory approval taking a year or longer.

Postmarketing Surveillance

Phase IV process to study the drug's long-term or rare adverse effects after it has been marketed.

Clinical Trials

Research studies that assess a candidate drug's pharmacological properties in humans.